Abstract
Arguably, the most common structure currently adopted for oncology modelling is the three-state partitioned survival model with the following states: stable disease, post-progression and dead. This design can, therefore, be adopted to capture the progressive nature of cancer. This chapter outlines the three-state model approach as well as introducing several other key aspects of economic modelling in oncology.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Bradbury MJ, Clark TG, Love SB et al (2003) Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. Br J Cancer 89(4):605–611
Clark TG, Bradburn MJ, Love SB et al (2003) Survival analysis part I: basic concepts and first analyses. Br J Cancer 89(2):232–238
Davis S (2014) Assessing technologies that are not cost-effective at a zero price. Report by the NICE Decision Support Unit. University of Sheffield
Guyot P, Welton NJ, Ouwens MJ et al (2011) Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness. Value Health 14(5):640–646
Guyot P, Ades AE, Ouwens MJ et al (2012) Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol 12:9
Guyot P, Ades AE, Beasley M (2017) Extrapolation of survival curves from cancer trials using external information. Med Decis Making 35:353–366
Hoyle MW, Henley W (2011) Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol 11:139
Ishak KJ, Proskorovsky I, Benedict A (2015) Simulation and matching-based approaches for indirect comparison of treatments. Pharmacoeconomics 33(6):537–549
Latimer N (2013). Nice DSU Technical Support Document. Survival analysis for economic evaluations alongside clinical trials–extrapolation with patient-level data
Latimer NR, Abrams KR, Lambert PC et al (2017) Adjusting for treatment switching in randomised controlled trials—a simulation study and a simplified two-stage method. Stat Methods Med Res 26:724–751
NICE (2013) Guide to the methods of technology appraisal, London, UK
NICE (2009) Appraising life-extending, end of life treatments. National Institute for Health and Care Excellence. Available from: http://www.nice.org.uk/guidance/gid-tag387/resources/appraising-life-extending-end-of-life-treatments-paper2
Woods B, Sideris E, Palmer S et al (2017) NICE DSU technical support document 19: partitioned survival analysis for decision modelling in health care—a critical review, Sheffield, UK
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Green, W., Taylor, M. (2019). Recent Developments in Health Economic Modelling of Cancer Therapies. In: Walter, E. (eds) Regulatory and Economic Aspects in Oncology. Recent Results in Cancer Research, vol 213. Springer, Cham. https://doi.org/10.1007/978-3-030-01207-6_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-01207-6_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01206-9
Online ISBN: 978-3-030-01207-6
eBook Packages: MedicineMedicine (R0)